- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Orphan drug status for targeted CLL treatment
Emergent BioSolutions announced this week that the US Food & Drug Association has granted the company orphan drug status to its sole oncology drug product TRU-016 for the treatment of chronic lymphocytic leukemia (CLL).
TRU-016 is a novel CD37-targeted therapy.
Emergent BioSolutions is currently running a handful of Phase I clinical trials testing the safety of TRU-016 in humans with CLL and similar B-cell malignancies such as non-Hodgkin's lymphomas.
Source: Emergent BioSolutions